Lansoprazole
Cat. No.：YN250551
| 产品名称: | Lansoprazole |
| CAS No.: | 103577-45-3 |
| Chemical Name: | 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole |
| Synonyms: | 兰索拉唑; AG-1749 |
| 分子量: | 369.36 |
| 分子式: | C₁₆H₁₄F₃N₃O₂S |
| SMILES: | O=S(C1=NC2=CC=CC=C2N1)CC3=NC=CC(OCC(F)(F)F)=C3C |
| 存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
| 运输: | Room temperature in continental US; may vary elsewhere. |
| 产品描述: | Lansoprazole (AG 1749) 是质子泵抑制剂，能抑制胃酸生成。Lansoprazole (AG 1749) 是中性鞘磷脂酶(N-SMase)的抑制剂(外泌体抑制剂)。 |
| IC50和靶点: | |
| In Vitro: | |
| In Vivo: | |
| Clinical Trial: | |
| Solvent & Solubility: |
Nagaya, H., Satoh, H., Kubo, K., et al.Possible mechanism for the inhibition of gastric (H+ + K+)-adenosine triphosphatase by the proton pump inhibitor AG-1749J. Pharmacol. Exp. Ther.248(2),799-805(1989)
Schubert, M.L.Pharmacotherapy for acid/peptic disordersYale J. Biol. Med.69(2),197-201(1996)
Richardson, P., Hawkey, C.J., and Stack, W.A.Proton pump inhibitors. Pharmacology and rationale for use in gastrointestinal disordersDrugs56(3),307-335(1998)
Klotz, U.Pharmacokinetic considerations in the eradication of Helicobacter pyloriClin. Pharmacokinet.38(3),243-270(2000)
